☆ 4.4 Article

Vaccine-induced immune thrombotic thrombocytopenia

LANCET HAEMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Andreas Greinacher et al.

Summary: The mechanism underlying vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily involves the formation of PF4/vaccine complexes and the proinflammatory environment stimulated by the vaccine, leading to the production of high-titer anti-PF4 antibodies in the body and consequent thrombosis.

BLOOD (2021)

Add to Collection

Article Hematology

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede et al.

Summary: This study reports 5 cases of prothrombotic immune thrombocytopenia following vaccination with AZD1222. Patients presented with various clinical manifestations, including thrombocytopenia and elevated D-dimer levels. Treatment experience suggests that anticoagulation may be effective, but there is also a risk of unusual and severe thromboembolic events.

BLOOD (2021)

Add to Collection

Article Hematology

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination

Stefan Handtke et al.

Summary: Vaccination plays a crucial role in combating the pandemic caused by the SARS-CoV-2 virus. The rare complication of thrombocytopenia and thrombotic complications after ChAdOx1 nCov-19 vaccination can be identified using a widely applicable whole-blood standard flow cytometric assay, allowing for rapid diagnosis by many laboratories.

BLOOD (2021)

Add to Collection

Review Hematology

COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome

Massimo Franchini et al.

Summary: This concise review summarizes the epidemiologic and pathogenic mechanisms of vaccine-associated immune thrombosis and thrombocytopenia (VITT). A total of 40 VITT cases have been reported, emphasizing the need for continuous pharmacovigilance monitoring to collect more data and optimize patient management.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Editorial Material Hematology

A new enemy is emerging in the fight against the SARS-CoV-2 pandemic

Francesco Rodeghiero et al.

HAEMATOLOGICA (2021)

Add to Collection

Editorial Material Hematology

Post-mortem findings in vaccine-induced thrombotic thombocytopenia

Cristoforo Pomara et al.

HAEMATOLOGICA (2021)

Add to Collection

Review Hematology

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Johannes Oldenburg et al.

HAMOSTASEOLOGIE (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Immunology

Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection

Dennis McGonagle et al.

Summary: The study explores the involvement of venous immunothrombotic mechanisms in SARS-CoV-2 infection and anti-SARS-CoV-2 DNA vaccination. It suggests that both SARS-CoV-2 infection and DNA vaccines may activate immune responses leading to autoimmunity and thrombosis, particularly in the venous system.

JOURNAL OF AUTOIMMUNITY (2021)

Add to Collection

Article Hematology

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology

Ishac Nazy et al.

Summary: Vaccine administration is ongoing worldwide to combat the COVID-19 pandemic, with newly developed vaccines showing high effectiveness but concerns over rare thrombotic events associated with the AstraZeneca ChadOx1 nCov-19 vaccine. The ISTH SSC Subcommittee on Platelet Immunology has outlined guidelines on how to recognize, diagnose, and manage patients with VITT, which presents clinically and pathologically similar to heparin-induced thrombocytopenia.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

Sean Platton et al.

Summary: Commercially available assays in the UK showed poor sensitivity for detecting anti-PF4 antibodies in suspected VITT patients when compared to ELISA testing. No superiority of IgG-ELISAs over polyspecific ELISAs in sensitivity to VITT was demonstrated, and no single ELISA method detected all possible/probable VITT cases. If a single ELISA test is negative, a second ELISA or platelet activation assay should be considered for cases with strong clinical suspicion.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine

Swathi Sangli et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Clinical Neurology

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany

Joerg B. Schulz et al.

Summary: The study found a higher incidence of cerebral sinus and venous thrombosis (CVT) after ChAdOx1 vaccination in Germany, especially among females. Among the 45 CVT patients, 26 were highly probable cases of vaccine-induced immune thrombotic thrombocytopenia (VITT).

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know

Gowthami M. Arepally et al.

BLOOD (2021)

Add to Collection

Article Hematology

The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia

Guenalp Uzun et al.

BLOOD (2021)

Add to Collection

Article Hematology

Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes

Sanjay Khandelwal et al.

Summary: HIT is a prothrombotic disorder involving ultra-large immune complexes that activate complement and contribute to cell deposition. Understanding the role of complement activation in HIT ULICs can help identify new targets for therapy and provide insights into immune complex-mediated thrombotic disorders.

BLOOD (2021)

Add to Collection

Article Hematology

Anti-Platelet Factor 4 Antibodies Causing VITT do not Cross-React with SARS-CoV-2 Spike Protein

Andreas Greinacher et al.

BLOOD (2021)

Add to Collection

Review Hematology

Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia

Emmanuel J. Favaloro

Summary: The COVID-19 pandemic has led to the production of vaccines to prevent infection, but there have been reports of rare thrombotic events post vaccination, particularly with adenovirus-based vaccines. Different terms have been used to describe this vaccine-induced condition, and testing methods vary, leading to potential differences in patient identification.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis

Benjamin Marchandot et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Add to Collection

Article Medicine, General & Internal

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Richard J. Perry et al.

Summary: The study documented cases of cerebral venous thrombosis after COVID-19 vaccination, finding that patients with VITT were younger, had more intracranial and extracranial thrombosis, and experienced worse outcomes compared to non-VITT patients. Treatments with non-heparin anticoagulants and intravenous immunoglobulin may improve outcomes in VITT-associated cerebral venous thrombosis.

LANCET (2021)

Add to Collection

Letter Infectious Diseases

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Matthias Tenbusch et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia

Angela Huynh et al.

Summary: Alanine-scanning mutagenesis is used to identify the PF4 epitope that is recognized by anti-PF4 antibodies in patients with vaccine-induced immune thrombotic thrombocytopaenia, revealing that the epitope corresponds to the heparin-binding site on PF4. VITT anti-PF4 antibodies show stronger binding response compared to HIT anti-PF4 antibodies, potentially contributing to platelet activation and thrombosis by mimicking the effect of heparin binding on PF4. The findings suggest a potential mechanism for VITT development related to immune complexes formation and platelet activation via Fc gamma receptor IIa.

NATURE (2021)

Add to Collection

Review Medicine, General & Internal

Cerebral Venous Thrombosis

Allan H. Ropper et al.

Summary: Cerebral venous thrombosis is a rare complication characterized by infarction, focal neurologic deficits, increased intracranial pressure, and often accompanied by disseminated intravascular coagulation and hemorrhage, particularly observed in some Covid-19 vaccines.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Sue Pavord et al.

Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination

Guenalp Uzun et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia

Christopher J. Patriquin et al.

Summary: Therapeutic plasma exchange was effective in treating refractory VITT in three patients, who showed poor response to initial therapy with anticoagulants and intravenous immune globulin. Their conditions improved and they were discharged from the hospital after the treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Decline in Pathogenic Antibodies over Time in VITT

Linda Schoenborn et al.

Summary: The study found that pathogenic antibodies in VITT patients decreased after receiving adenoviral vector Covid-19 vaccines, with improvements in platelet activation despite persistent positivity on ELISA. Additionally, 5 patients received additional vaccination without any sequelae.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Alex Bourguignon et al.

Summary: High-dose intravenous immune globulin (IVIG) combined with anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), showing a good response in reducing antibody-induced platelet activation, particularly in cases of VITT induced by ChAdOx1 nCoV-19 vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Hematology

Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia

Theodore E. Warkentin et al.

Summary: Heparin-induced thrombocytopenia (HIT) is characterized by thrombocytopenia, hypercoagulability, and increased thrombosis risk, with platelet-activating anti-PF4/heparin antibodies. Non-heparin medications and naturally-occurring polyanions can also trigger HIT. Spontaneous HIT syndrome can occur without prior exposure to heparin or polyanionic medications. COVID-19 vaccination has been associated with a similar disorder, Vaccine-induced immune thrombotic thrombocytopenia (VITT), featuring unusual thromboses.

THROMBOSIS RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Alex Bourguignon et al.

Summary: The use of high-dose IVIG plus anticoagulation is recommended for the treatment of VITT, a rare side effect of adenoviral vector vaccines against Covid-19. Response to IVIG therapy in VITT patients showed reduced platelet activation and improvement in symptoms.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS)

Stavros Konstantinides et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Gastroenterology & Hepatology

ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation

Douglas A. Simonetto et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Review Hematology

Current imaging modalities for diagnosing cerebral vein thrombosis - A critical review

Lisette F. van Dam et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Hematology

Anticoagulant therapy for splanchnic vein thrombosis ISTH SSC Subcommittee Control of Anticoagulation

Marcello Di Nisio et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

X. Long Zheng et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Multidisciplinary Sciences

Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia

Jose Perdomo et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Review Hematology

High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review

Theodore E. Warkentin

EXPERT REVIEW OF HEMATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pulmonary embolism

Menno V. Huisman et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection

Article Multidisciplinary Sciences

Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity

Thi-Huong Nguyen et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Hematology

Further insights into the anti-PF4/heparin IgM immune response

Krystin Krauel et al.

THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Article Hematology

Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors

Jerome Rollin et al.

THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Article Medicine, General & Internal

Heparin-Induced Thrombocytopenia

Andreas Greinacher

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Hematology

How I treat splanchnic vein thrombosis

Walter Ageno et al.

BLOOD (2014)

Add to Collection

Review Hematology

Diagnostic management of acute deep vein thrombosis and pulmonary embolism

M. V. Huisman et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)

Add to Collection

Article Cell Biology

Platelet-adenovirus vs. inert particles interaction: Effect on aggregation and the role of platelet membrane receptors

Elena Gupalo et al.

PLATELETS (2013)

Add to Collection

Review Hematology

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Cindy Neunert et al.

BLOOD (2011)

Add to Collection

Article Hematology

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer

Raul Alba et al.

BLOOD (2009)

Add to Collection

Article Hematology

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance

Maha Othman et al.

BLOOD (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.